Quantcast
Home > Quotes > LXRX
LXRX

Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Quote & Summary Data

$8.25
*  
0.47
5.39%
Get LXRX Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading LXRX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    LXRX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
21
Today's High / Low
$ 8.70 / $ 8.19
Share Volume
370,832
50 Day Avg. Daily Volume
404,788
Previous Close
$ 8.72
52 Week High / Low
$ 13.97 / $ 7.42
Market Cap
873,884,567
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.26
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1

Intraday Chart

Shares Traded

Share Volume:
370,832
50 Day Avg. Daily Volume:
404,788

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.26

Trading Range

The current last sale of $8.25 is 11.19% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.70 $ 13.97
 Low: $ 8.19 $ 7.42

Company Description (as filed with the SEC)

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of breakthrough treatments for human disease. We are presently devoting most of our resources to the commercialization or development of our four most advanced drug programs: * We have obtained approval from the U.S. Food and Drug Administration, or FDA, to sell our first commercial product, XERMELO® (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy. We have commenced sales and marketing of XERMELO, and it is commercially available to patients in the United States.  ... More ...  


Risk Grade

Where does LXRX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 8.70
Open Date:
Nov. 19, 2018
Close Price:
$ 8.25
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x